Study to Evaluate Safety & Effectiveness of Vascular Sealant System

This study has been terminated.
(Business Decision)
Sponsor:
Information provided by (Responsible Party):
Covidien ( Confluent Surgical )
ClinicalTrials.gov Identifier:
NCT00439309
First received: February 21, 2007
Last updated: February 17, 2014
Last verified: February 2014

February 21, 2007
February 17, 2014
April 2007
May 2008   (final data collection date for primary outcome measure)
Sealing Success [ Time Frame: Within 10 minutes following restoration of blood flow ] [ Designated as safety issue: Yes ]
The primary effectiveness endpoint is sealing success defined as complete anastomotic suture line sealing within 10 minutes following restoration of blood flow without use of an adjunctive hemostatic technique different from the assigned treatment. The primary effectiveness endpoint was evaluated on a per subject basis. For subjects with two treated sites, the subject is considered a success only if there is complete anastomotic suture line sealing within 10 minutes at both sites.
Not Provided
Complete list of historical versions of study NCT00439309 on ClinicalTrials.gov Archive Site
  • Proportion of Immediate Sealing Success at Treated Anastomoses (Anastomoses Level) [ Time Frame: 60 seconds post restoration of blood flow ] [ Designated as safety issue: Yes ]
    A site with no suture line bleeding after blood flow is restored and monitored for a minimum period of 60 seconds to confirm cessation of blood flow
  • Proportion of Overall Sealing Successes at Treated Anastomoses (Anastomoses Level) [ Time Frame: Within 10 minutes post restoration of blood flow ] [ Designated as safety issue: Yes ]
    A site with no suture line bleeding after blood flow is restored and monitored for a minimum period of 60 seconds to confirm cessation of blood flow.
  • Time to Hemostasis [ Time Frame: Within 10 minutes post restoration of blood flow ] [ Designated as safety issue: Yes ]
    Time to hemostasis determined from time circulation restored after treatment application until bleeding stopped (assessed at intervals of immediate, 1, 3, 5, 7.5 and 10 min). For subject with two sites, time to hemostasis of both sites used for analysis. Subjects for whom bleeding had not stopped within 10 min considered censored observations.
  • Time to Wound Closure [ Time Frame: From initial clamp removal at the last anastomotic site until skin closure ] [ Designated as safety issue: Yes ]
    Time to wound closure was defined as the elapsed time between initial clamp removal at the last anastomotic site until skin closure. This endpoint was analyzed using the log-rank test to compare the two treatment groups. The Kaplan-Meier method was used to obtain estimated median times to wound closure and the corresponding 95% confidence intervals for each treatment group.
Not Provided
Not Provided
Not Provided
 
Study to Evaluate Safety & Effectiveness of Vascular Sealant System
Randomized Study to Evaluate Safety & Effectiveness of Vascular Sealant to Control Suture Line Bleeding

To evaluate a new vascular sealant compared to control for the control of suture line bleeding after vascular reconstructive surgery.

Vascular surgery encompasses a wide range of surgical procedures. In these procedures reduction of blood loss and creation of suture line is of utmost importance to the surgeon. Bleeding at the suture line may require transfusion, as well as prolonged operative and anesthesia time. Suture hole bleeding is common following using synthetic and biological grafts for vascular repair. Several topical hemostatic ans sealing agents have been developed to control suture line bleeding. This new vascular sealant possess high bonding properties, minimal tissue reaction, is biodegradable and absorbed by the body quickly. The primary focus of this study is to compare the safety and effectiveness of the vascular sealant with standard of care methods used today, specifically gelfoam/thrombin and sponge like material.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Peripheral Vascular Disease
  • Device: Gelfoam/Thrombin
    Gelfoam/Thrombin
    Other Name: absorbable gelatin compressed sponge
  • Device: VascuSeal
    VascuSeal
    Other Name: Vascular Sealant System
  • Experimental: VascuSeal
    Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
    Intervention: Device: VascuSeal
  • Active Comparator: GELFOAM/THROMBIN
    GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
    Intervention: Device: Gelfoam/Thrombin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
69
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

Subject was > 18 years of age. Scheduled for elective vascular surgery that entails placement of a PTFE vascular graft including extra-anatomic, infrainguinal bypass, and primary and secondary arteriovenous access procedures. Subject was willing and able to comply with all aspects of the treatment and evaluation schedule. Informed of the nature of the study, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site

Exclusion Criteria:

Subject had a known local or systemic infection. Subjects with known coagulopathies including hemophilia, factor deficiencies, platelet count < 80,000 u/mL, heparin induced thrombocytopenia or uncorrected INR > 1.5. Subject was participating in a clinical trial that requires treatment with another investigational device or drug. Subject was lactating or pregnant, or does not agree to use contraception for the duration of the study. Subject had a known hypersensitivity to any components of bovine thrombin preparations and/or material of bovine origin. The investigator determined that the subject should not be included in the study for reason(s) not already specified

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00439309
VAS-06-001
Yes
Covidien ( Confluent Surgical )
Confluent Surgical
Not Provided
Study Director: Vladimir I Scerbin Confluent Surgical
Covidien
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP